Gene therapy for urea cycle defects: An update from historical perspectives to future prospects
Journal of Inherited Metabolic Disease · 2024-01 · 47 (1) · 50-62
DOI: 10.1002/jimd.12609 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 18.04.2023. Verfasst von Claire Duff und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, London, UK. Hauptthemen laut MEDLINE: Ornithine Carbamoyltransferase Deficiency Disease, Liver Transplantation, Urea Cycle Disorders, Inborn. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, MRF, Medical Research Foundation.
Abstract (Originalsprache)
Urea cycle defects (UCDs) are severe inherited metabolic diseases with high unmet needs which present a permanent risk of hyperammonaemic decompensation and subsequent acute death or neurological sequelae, when treated with conventional dietetic and medical therapies. Liver transplantation is currently the only curative option, but has the potential to be supplanted by highly effective gene therapy interventions without the attendant need for life‐long immunosuppression or limitations imposed by donor liver supply. Over the last three decades, pioneering genetic technologies have been explored to circumvent the consequences of UCDs, improve quality of life and long‐term outcomes: adenoviral vectors, adeno‐associated viral vectors, gene editing, genome integration and non‐viral technology with messenger RNA. In this review, we present a summarised view of this historical path, which includes some seminal milestones of the gene therapy's epic. We provide an update about the state of the art of gene therapy technologies for UCDs and the current advantages and pitfalls driving future directions for research and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, London, UK.
- Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospitals Network, Westmead, New South Wales, Australia.
- Discipline of Child and Adolescent Health, The University of Sydney, Westmead, New South Wales, Australia.
- National Institute of Health Research Great Ormond Street Biomedical Research Centre, London, UK.
- Metabolic Medicine Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
ORCID-Profile: Julien Baruteau
Förderung
- Medical Research Council
- MRF
- Medical Research Foundation
Zitieren
APA
Duff, C., Alexander, I. E., & Baruteau, J. (2024). Gene therapy for urea cycle defects: An update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease, 47(1), 50-62. https://doi.org/10.1002/jimd.12609
Vancouver
Duff C, Alexander IE, Baruteau J. Gene therapy for urea cycle defects: An update from historical perspectives to future prospects. Journal of Inherited Metabolic Disease. 2024;47(1):50-62. doi:10.1002/jimd.12609
BibTeX
@article{Duff2024,
author = {Duff, Claire and Alexander, Ian E and Baruteau, Julien},
title = {Gene therapy for urea cycle defects: An update from historical perspectives to future prospects},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
volume = {47},
number = {1},
pages = {50--62},
doi = {10.1002/jimd.12609}
}
EUVIMED